SCHEMBL31546427

SCHEMBL31546427

O=C(NCCCN1CCC(Cc2ccccc2F)CC1)N1CCN(c2nc(-c3ccc(OC(F)(F)F)cc3)no2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ HTT P42858 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ TP53 P04637 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ GAA P10253 2/20 0.48
▸ CHRM4 P08173 3/20 0.47
▸ MAPT P10636 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CCR2 P41597 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CCR3 P51677 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ CHRM2 P08172 2/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30584948 0.90 LMNA (0.52) TSHRSMN1; SMN2HTTLMNATP53
SCHEMBL30584805 0.88 LMNA (0.48) TSHRSMN1; SMN2HTTLMNATP53
SCHEMBL30584888 0.85 DRD2 (0.51) TSHRSMN1; SMN2HTTLMNATP53
SCHEMBL31546418 0.81 LMNA (0.72) TSHRSMN1; SMN2HTTLMNATP53
SCHEMBL30584882 0.79 LMNA (0.46) TSHRSMN1; SMN2HTTLMNATP53
SCHEMBL25434754 0.79 MEN1 (0.56) TSHRSMN1; SMN2HTTLMNATP53
Formic Acid SCHEMBL30584790 0.79 MEN1 (0.56) TSHRSMN1; SMN2HTTLMNATP53
SCHEMBL31667543 0.79 LMNA (0.58) TSHRSMN1; SMN2HTTLMNATP53
SCHEMBL30584727 0.79 LMNA (0.47) TSHRSMN1; SMN2HTTLMNATP53
SCHEMBL30584818 0.78 MEN1 (0.60) TSHRSMN1; SMN2HTTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 TSHR 4347/4885SMN1; SMN2 3115/4885HTT 2290/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 TSHR 4347/4885SMN1; SMN2 3115/4885HTT 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback